INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2016

Fasting up to 72 hours around platinum-based chemotherapy was feasible and safe in cancer patients.

Researchers tested dose-escalation of fasting (24, 48, or 72 hours around chemotherapy) in 20 cancer patients receiving platinum-based regimens. Feasibility criteria were met, with fasting-related toxicities limited to grade 2 or lower (most commonly fatigue, headache, and dizziness). Leukocyte DNA damage showed a non-significant reduction in subjects fasting ≥48 hours (p = 0.08), and a non-significant trend toward less grade 3 or 4 neutropenia was observed in the 48 and 72 hour cohorts versus the 24 hour cohort (p = 0.17). IGF-1 levels decreased by 30%, 33%, and 8% in the 24, 48, and 72 hour fasting cohorts, respectively, after the first fasting period.

Study type
Dose-escalation feasibility trial
Who was studied
20 cancer patients receiving platinum-based chemotherapy (median age 61, 85% women)
What was measured
Feasibility, safety/toxicity, oxidative stress/DNA damage in leukocytes, and fasting biomarkers (IGF-1, glucose, insulin, ketones, IGFBPs)

THE PAPER

Safety and feasibility of fasting in combination with platinum-based chemotherapy.

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. BMC Cancer, 2016.

PubMed 27282289 ↗DOI 10.1016/j.stem.2014.04.014 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.